Guardant Health, Inc.
GH
Helyezés a részvények között
#1077
Guardant Health, Inc., established in Redwood City, California, in 2011, is a... Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.
Részvényárfolyam
$169.16
Piaci kapitalizáció
$22.70B
Változás (1 nap)
4.04%
Változás (1 év)
150.57%
Ország
US
Kereskedés Guardant Health, Inc. (GH)
Kategória
Healthcare
Bevétel a(z) Guardant Health, Inc. (GH) részvényhez
Bevétel ekkor: Jun 2026 TTM: $1.18B
Guardant Health, Inc. legfrissebb pénzügyi jelentései szerint a vállalat jelenlegi árbevétele (TTM) $1.18B. 2023 évben a vállalat $563.95M árbevételt ért el, amely növekedés a 2022 évben elért $449.54M árbevételhez képest. Az árbevétel az a teljes összeg, amit a vállalat termékek vagy szolgáltatások eladásából generál. A nyereséggel ellentétben ebből nem vonódnak le költségek.
Guardant Health, Inc. bevételtörténete 2016 és 2026 között
Bevétel az év végén
| Év | Bevétel | Változtassa meg |
|---|---|---|
| 2026 (TTM) | $1.18B | 60.09% |
| 2024 | $739.02M | 31.04% |
| 2023 | $563.95M | 25.45% |
| 2022 | $449.54M | 20.31% |
| 2021 | $373.65M | 30.32% |
| 2020 | $286.73M | 33.75% |
| 2019 | $214.38M | 136.52% |
| 2018 | $90.64M | 81.85% |
| 2017 | $49.84M | 97.40% |
| 2016 | $25.25M | 0.00% |
Hasonló cégek vagy versenytársak bevétele
| Vállalat | Bevétel | Bevételkülönbség | Ország |
|---|---|---|---|
| $46.34B | 3,816.47% |
US
|
|
| $25.11B | 2,022.13% |
US
|
|
| $2.71B | 128.81% |
US
|
|
| - | - |
CN
|
|
| $7.37B | 523.11% |
US
|
